Evidence map›Paper›PMID 38663550›Full record

ReviewAdvanced drug delivery reviews2024

Nanoparticle-neutrophils interactions for autoimmune regulation.

Daniel Kupor, Michael L Felder, Shivanie Kodikalla, Xueqi Chu, Omolola Eniola-Adefeso

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. mFrontiers in immunology · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Daniel KuporDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Michael L FelderDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Shivanie KodikallaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Xueqi ChuDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Omolola Eniola-AdefesoDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: lolaa@umich.edu.
University of Michigan · US

Funding

Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Development of PolyAspirin Particles for Therapeutic Intervention in ALI/ARDS via the Passive Restraint of Neutrophil FunctionR01HL145709 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SINGER, BENJAMIN HERSCHEL · 2020 to 2023
$1.6M
NHLBI NIH HHS R01 HL145709NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Neutrophils play an essential role as 'first responders' in the immune response, necessitating many immune-modulating capabilities. Chronic, unresolved inflammation is heavily implicated in the progression and tissue-degrading effects of autoimmune disease. Neutrophils modulate disease pathogenesis by interacting with the inflammatory and autoreactive cells through effector functions, including signaling, degranulation, and neutrophil extracellular traps (NETs) release. Since the current gold standard systemic glucocorticoid administration has many drawbacks and side effects, targeting neutrophils in autoimmunity provides a new approach to developing therapeutics. Nanoparticles enable targeting of specific cell types and controlled release of a loaded drug cargo. Thus, leveraging nanoparticle properties and interactions with neutrophils provides an exciting new direction toward novel therapies for autoimmune diseases. Additionally, recent work has utilized neutrophil properties to design novel targeted particles for delivery into previously inaccessible areas. Here, we outline nanoparticle-based strategies to modulate neutrophil activity in autoimmunity, including various nanoparticle formulations and neutrophil-derived targeting.

Indexed as

Autoimmune DiseasesNanoparticlesNeutrophilsAnimalsAutoimmunityDrug Delivery SystemsHumansAutoimmune diseaseControlled releaseDrug deliveryImmune responseInflammationNanoparticlesNeutrophilsTargeting

Identifiers

PMID38663550
PMCPMC11246615
OpenAlexW4395053994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.